Literature DB >> 9179562

Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs.

K G Toft1, S O Hustvedt, D Grant, G A Friisk, T Skotland.   

Abstract

The metabolism of MnDPDP (manganese(II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate-5,5'-bis(phosphate) was studied in dogs after intravenous infusion for 12.5 min with either 10, 30 or 100 mumol MnDPDP/kg b.w. HPLC analyses of plasma samples obtained 1, 5 and 30 min after the end of infusion revealed that MnDPDP was rapidly dephosphorylated to MnDPMP (manganese(II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate-5-phosphate) and MnPLED (manganese(II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate), with simultaneous transmetallation to the corresponding zinc metabolites ZnDPDP, ZnDPMP and ZnPLED. In the low-dose group, the parent compound MnDPDP was present at the lowest concentration compared to the metabolites at the first sampling time point, 1 min after the end of infusion, whereas MnPLED was the main metabolic. At 30 min post-infusion ZnPLED was the main metabolite. The medium- and high-dose groups showed a similar metabolic pattern. In the high-dose group, MnPLED was the main metabolite at all sampling time points. The estimated plasma half-life of total ligand was 20 min, and it was dose-independent with an apparent volume of distribution of 0.2 l/kg. The rate of dephosphorylation was similar to the rate of transmetallation, and both were dose-independent. However, calculations of the total Mn and Zn ligands indicated that the apparent plasma elimination was dose-dependent. The half-life for total Mn ligands which is a combination of both metabolism and elimination, were 10 and 20 min at 10 and 100 mumol/kg, respectively. The half-life for total Zn ligands which is the half-life for rate of formation of Zn ligands, were 40 and 65 min at 10 and 100 mumol/kg, respectively. No sex differences in metabolic pattern were observed in any of the three dosage groups.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179562     DOI: 10.1007/BF03189786

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  13 in total

1.  Pharmacokinetic behavior of gadoteridol injection.

Authors:  S J McLachlan; S Eaton; D N De Simone
Journal:  Invest Radiol       Date:  1992-08       Impact factor: 6.016

2.  Isolation of a zinc alpha-2-macroglobulin from human serum.

Authors:  A F Parisi; B L Vallee
Journal:  Biochemistry       Date:  1970-06-09       Impact factor: 3.162

3.  Biodistribution and in vivo stability of manganese dipyridoxyl diphosphate in relation to imaging efficacy.

Authors:  D Grant; K Zech; E Holtz
Journal:  Invest Radiol       Date:  1994-06       Impact factor: 6.016

4.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers.

Authors:  H J Weinmann; M Laniado; W Mützel
Journal:  Physiol Chem Phys Med NMR       Date:  1984

5.  Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: detection and quantitation of the parent compound MnDPDP and metabolites in human plasma by high performance liquid chromatography.

Authors:  K G Toft; G A Friisk; T Skotland
Journal:  J Pharm Biomed Anal       Date:  1997-04       Impact factor: 3.935

6.  Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: in vitro metabolism and protein binding studies of the active component MnDPDP in human blood.

Authors:  K G Toft; G M Kindberg; T Skotland
Journal:  J Pharm Biomed Anal       Date:  1997-04       Impact factor: 3.935

7.  Pharmacokinetics and stability of caldiamide sodium in rats.

Authors:  O Okazaki; T Kurata; N Yoshioka; H Hakusui
Journal:  Arzneimittelforschung       Date:  1996-01

8.  Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging.

Authors:  N M Rofsky; J C Weinreb; M E Bernardino; S W Young; J K Lee; M E Noz
Journal:  Radiology       Date:  1993-07       Impact factor: 11.105

9.  Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging.

Authors:  G Elizondo; C J Fretz; D D Stark; S M Rocklage; S C Quay; D Worah; Y M Tsang; M C Chen; J T Ferrucci
Journal:  Radiology       Date:  1991-01       Impact factor: 11.105

10.  Cardiovascular toxicity and tissue proton T1 response to manganese injection in the dog and rabbit.

Authors:  G L Wolf; L Baum
Journal:  AJR Am J Roentgenol       Date:  1983-07       Impact factor: 3.959

View more
  4 in total

1.  In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes.

Authors:  Karen C Briley-Saebo; Tuyen Hoang Nguyen; Alexander M Saeboe; Young-Seok Cho; Sung Kee Ryu; Eugenia R Volkova; Eugenia Volkava; Stephen Dickson; Gregor Leibundgut; Philipp Wiesner; Philipp Weisner; Simone Green; Florence Casanada; Yury I Miller; Walter Shaw; Joseph L Witztum; Zahi A Fayad; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2012-02-07       Impact factor: 24.094

2.  Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging.

Authors:  Zipeng Zhen; Jin Xie
Journal:  Theranostics       Date:  2012-01-01       Impact factor: 11.556

3.  Manganese-Enhanced T1 Mapping in the Myocardium of Normal and Infarcted Hearts.

Authors:  N B Spath; D M L Lilburn; G A Gray; L M Le Page; G Papanastasiou; R J Lennen; R L Janiczek; M R Dweck; D E Newby; P C Yang; M A Jansen; S I Semple
Journal:  Contrast Media Mol Imaging       Date:  2018-10-25       Impact factor: 3.161

Review 4.  Manganese-Enhanced Magnetic Resonance Imaging: Overview and Central Nervous System Applications With a Focus on Neurodegeneration.

Authors:  Ryan A Cloyd; Shon A Koren; Jose F Abisambra
Journal:  Front Aging Neurosci       Date:  2018-12-13       Impact factor: 5.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.